Company & Sponsor Intelligence

Shire

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials21

Recruiting0

Completed19

Countries2

Therapeutic footprint

adhddepressioneating_disorders

Indexed studies

NCT01274221Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
adhd · United StatesPHASE3

NCT04085172A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
adhd · United StatesPHASE4

NCT01244490Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
adhd · United StatesPHASE3

NCT03327402Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
adhd · United StatesPHASE1

NCT03260205Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
adhd · United StatesPHASE3

NCT01291173Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
eating_disorders · United StatesPHASE2

NCT01718509SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
eating_disorders · United StatesPHASE3

NCT01010750Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
adhd · United StatesPHASE1

NCT04866043Drug Use Study With VYVANSE® in Australia for Binge Eating Disorder
eating_disorders · AustraliaCOMPLETED

NCT00557960ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomoxetine Hydrochloride) Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With ADHD
adhd · United StatesPHASE3

NCT00151996Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
adhd · PHASE2

NCT03325881Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
adhd · United StatesPHASE3

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →